Skip to Main Content

Over a career spanning more than three decades, Dr. Charles Sawyers played a key role in two blockbuster cancer drugs: Gleevec for chronic myelogenous leukemia and the prostate cancer drug Xtandi.

For those achievements,  Sawyers, a Howard Hughes Medical Institute investigator and chair of the Human Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer Center, was named the inaugural winner of the STAT Biomedical Innovation Award. Delivered at the STAT Summit in Cambridge, Mass., late last year, the award is presented to a top researcher in biomedicine whose work has helped to define their field — and, in the process, helped patients.

Sawyers also sat down with STAT reporter Megan Thielking at the summit for a conversation on his career and work in oncology.


Dr. Charles Sawyers receives the first-ever STAT Biomedical Innovation Award for his work in oncology. STAT